2022 American Transplant Congress
Long-Term Outcomes of Liver Transplantation (LT) Using Grafts from Donors with Active and Chronic Hepatitis B Virus (HBV) Infection; Multi-Center Cohort Study
*Purpose: Liver grafts from donors with hepatitis B infection contributed to expand the donor pool under the Hepatitis B immunoglobulin (HBIG) and antiviral agents (NA:…2022 American Transplant Congress
Safety and Efficacy at 4 Years in Post-Liver Transplant Patients with Chronic Kidney Disease Receiving Tenofovir Alafenamide (TAF) for HBV Prophylaxis
*Purpose: Recommended antiviral prophylaxis to prevent recurrent HBV infection after liver transplantation includes tenofovir disoproxil fumarate (TDF). However, given risks of bone/renal toxicity associated with…2022 American Transplant Congress
Immunity Rates to Hepatitis B Among Solid Organ Transplant Recipients
*Purpose: Immunosuppression after transplantation decreases vaccine responsiveness. Thus, to be best protected from post-transplant communicable diseases, vaccination of organ transplant candidates in the pre-transplant period…2022 American Transplant Congress
Compliance with OPTN Infectious Disease Testing
Massachusetts General Hospital, Boston, MA
*Purpose: Effective 3/1/21 OPTN policy requires all transplant recipients to have pre-transplant and post-transplant infectious disease testing performed at specific intervals: upon admission and prior…2022 American Transplant Congress
The Prevalence And Risk Factors Of De Novo Hepatitis B Virus Infection In Kidney Transplantation From Hepatitis B Antigen-positive Donors To Hbsag-negative Recipients
1urology, west china hospital, Chengdu, China, 2Urology, West China Hospital, Chengdu, China
*Purpose: To explore the prevalence and risk factors of de novo HBV infection (DNH) in kidney transplantation (KT) from HBsAg⁺ donors (D[HBsAg⁺]) to HBsAg-negative recipients…2021 American Transplant Congress
De Novo Hepatitis B Infection Following Liver Transplant with Hepatitis B Core Antibody Positive Graft
*Purpose: The risk of de novo HBV infection in liver transplant recipients of Hepatitis B core antibody (HBcAb) positive donor organs is tempered by availability…2021 American Transplant Congress
Impact of Non-active Hepatitis B on Patient Survival After Renal Transplantation
*Purpose: Dialysis patients (pts) have an increased risk for hepatitis B (HB) infection and impaired response to HB vaccine compared to the general population. As…2021 American Transplant Congress
Use of Hepatitis B N.A.T. Positive Kidneys in Hepatitis B Immune Recipients
*Purpose: There is an increasing demand for kidney donations as roughly 4000 people die on the waitlist each year while the number of kidneys being…2020 American Transplant Congress
Effects of Tenofovir and Entecavir on Glomerular Kidney Function in Liver Transplant Patients: A Nationwide Cohort Study
*Purpose: Entecavir and tenofovir are currently the first-line drugs in liver transplantation (LT) patients for the prevention of hepatitis B virus recurrence. Despite its proven…2020 American Transplant Congress
Renal Safety of Entecavir and Tenofovir with Hepatitis B Immunoglobulin in Liver Transplant Patients
*Purpose: Combination of potent nucleos(t)ide analougues (NAs) and hepatitis B immunoglobulin is recommended after liver transplantation for the prevention of hepatitis B virus (HBV) recurrence.…
- 1
- 2
- 3
- …
- 6
- Next Page »